Antiplatelet and calcium inhibitory properties of eugenol and sodium eugenol acetate.
1. Eugenol (3-methoxy-4-hydroxy-propenylbenzene) or sodium eugenol acetate (4-O-acetic acid sodium-3-methoxy-1-propenylbenzene) (0.25, 0.5, 1 mM) concentration-dependently inhibited arachidonic acid (AA)-, collagen-, epinephrine- and ADP-induced platelet aggregation. 2. Eugenol or sodium eugenol acetate inhibited collagen-induced aggregation of washed rabbit platelets synergistically with creatine phosphate/creatine phosphokinase (CP/CPK, 5 mM/10 U/ml) or p-bromophenacyl bromide (p-BPB, 10 microM), and they also potentiated the inhibitory action of imidazole (0.5 mM) on AA-induced aggregation. 3. Eugenol or sodium eugenol acetate (0.25, 0.5, 1 mM) concentration-dependently inhibited AA-induced thromboxane B2 and prostaglandin E2 formation. 4. The rise of intracellular Ca2+ caused by collagen, epinephrine, ADP, and AA were inhibited by eugenol or sodium eugenol acetate (1 mM).
Chen
S J
SJ
Department of Pharmacology, Kaohsiung Medical College, Taiwan, Republic of China.
Wang
M H
MH
Chen
I J
IJ
D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000097:blood*; D003600:Cytosol / Q000187:drug effects / Q000378:metabolism; D015232:Dinoprostone / Q000378:metabolism; D005054:Eugenol / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*; D066298:In Vitro Techniques; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology*; D011817:Rabbits; D013929:Thromboxane B2 / Q000378:metabolism
D010975:Platelet Aggregation Inhibitors; C102809:sodium eugenol acetate; D005054:Eugenol; D013929:Thromboxane B2; D015232:Dinoprostone; D002118:Calcium